Generate a tailored SOP for Dr. Sebastian Kobold. Improve your application with a focused, well-structured draft.
Sebastian Kobold is the director of the Kobold Lab at the Institute of Clinical Pharmacology. His research focuses on immunopharmacology, particularly in the fields of CAR T-cell therapy and antibody therapies for cancer. Kobold is involved in the development of innovative strategies to improve cellular therapies in solid tumors and leukemias, with an emphasis on overcoming the challenges associated with tumor microenvironments. He has led various funded projects aimed at enhancing T cell efficacy and investigating the interactions between tumor cells and the immune system. His work examines critical cytokine interactions, particularly focusing on the effects of interleukin-22 in cancer progression. Kobold holds multiple grants and has published extensively on the topics of immunotherapy and cellular engineering in cancer treatment. He aims to translate research findings into clinical applications that enhance patient outcomes in oncology.
Kobold Lab, Institute of Clinical Pharmacology • München
Oversees research initiatives in immunopharmacology, focusing on CAR T-cell therapies and the development of new immunotherapeutic strategies.
Administered by the Faculty of Economics. GRE is NOT required for the standard M.Sc. Economics.